MetaCap

Amphastar Pharmaceuticals (AMPH) vs Harrow (HROW)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Amphastar Pharmaceuticals (AMPH) has outperformed Harrow (HROW) over the past year, gaining 8.6% versus a loss of 21.8%. Over five years, HROW leads with a +196.1% price change compared with +41.9% for AMPH. Amphastar Pharmaceuticals is the larger company by market cap ($1.20 billion vs $1.14 billion), about 1.1 times the size, while Harrow is growing revenue faster (+36.4% vs -1.7%).

On valuation, Amphastar Pharmaceuticals trades at a lower forward P/E (8.4x vs 16.3x for Harrow). Amphastar Pharmaceuticals converts more of its revenue into profit, with a net margin of 13.6% versus -1.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMPH+8.61%HROW-21.85%
+45%+3%-39%
Nov 21, 20251 yearNov 20, 2026
AMPH+37.74%HROW+181.31%
+456%+193%-69%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMPH versus HROW key metrics
MetricAMPHHROW
Share price$28.25$30.41
Market cap$1.20B$1.14B
1-day change+0.50%-5.35%
YTD return+5.49%-37.94%
1-year return+8.61%-21.85%
5-year return+41.89%+196.11%
P/E ratio (TTM)12.96—
Forward P/E8.4316.26
EPS (TTM)$2.18$-0.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$719.89M$272.30M
Revenue growth (YoY)-1.65%+36.41%
Net income (latest FY)$98.09M$-5.14M
Gross margin49.46%75.05%
Operating margin19.50%11.21%
Net margin13.63%-1.89%
52-week high$31.00$54.85
52-week low$16.65$25.76
Distance from 52-week high-8.87%-44.56%
Analyst consensusholdstrong_buy
Avg. price target upside-13.27%+104.70%
Average volume475.35K626.20K
Shares outstanding42.65M37.53M
Employees1,976373
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AMPH has outperformed HROW by 30.5 percentage points over the past year.
  • Amphastar Pharmaceuticals is more profitable, keeping 13.6 cents of every revenue dollar as net income versus -1.9 cents for Harrow.
  • Harrow grew revenue faster in its latest fiscal year (+36.41% vs -1.65%).

About Amphastar Pharmaceuticals

AMPH stock →

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees

About Harrow

HROW stock →

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees

AMPH vs HROW FAQ

Which is bigger, Amphastar Pharmaceuticals or Harrow?

Amphastar Pharmaceuticals (AMPH) is larger, with a market capitalization of $1.20B compared with $1.14B for Harrow (HROW).

Which stock has performed better over the past year, AMPH or HROW?

AMPH returned +8.61% over the past 12 months, compared with -21.85% for HROW (price return, excluding dividends). Past performance does not predict future results.

Are Amphastar Pharmaceuticals and Harrow in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons